PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 10, 2025Journal of Precision Oncology0 citations

Complete Response to Targeted Therapy in SDHB-Mutated Metastatic Paraganglioma

Complete Response to Sequential Peptide Receptor Radionuclide Therapy and Sunitinib in SDHB-mutated Metastatic Paraganglioma

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAmrit Kaur KalerSUSmrity UpadhyaySSShalaka Satpute

Discussion

Loading...

Member takes

Overview

A case of precision medicine shows complete resolution of metastatic paraganglioma using sunitinib and PRRT.

Key Points

  • Complete resolution of metastatic lesions was achieved after combining sunitinib with peptide receptor radionuclide therapy.
  • The patient had a confirmed SDHB mutation with a 71% allelic burden, contributing to a high malignancy risk.
  • The importance of genetic testing is emphasized, particularly in young patients with neuroendocrine tumors.
  • Personalized treatment approaches can significantly impact outcomes in rare cases of metastatic paraganglioma.

Cite This Study

Kaler et al. (2025) studied this question.

synapsesocial.com/papers/68c18f409b7b07f3a0615dc9https://doi.org/10.4103/jpo.jpo_5_25
View Full Paper
Ask AI
Bookmark
Share